Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Parkinson disease”

Parkinson's Foundation PD GENEration Genetic RegistryRecruiting
NCT04994015N/AUpdated Sep 8, 2026
Sponsor: Parkinson's Foundation
Parkinson's Disease
United States, Canada, Israel
Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseRecruiting
NCT06949670N/AUpdated Sep 8, 2026
Sponsor: Tianjin Medical University
Alpha Synuclein Pathology · Alpha-Synuclein · Parkinson Disease
China
Early Detection of Selected Neuropathologies in Motor Vehicle DriversRecruiting
NCT07360886N/AUpdated Sep 8, 2026
Sponsor: University Hospital Olomouc
Multiple Sclerosis · Parkinson Disease
Czechia
Parkinson Progression Marker Initiative Online (PPMI Online)Recruiting
NCT05065060N/AUpdated Sep 8, 2026
Sponsor: Michael J. Fox Foundation for Parkinson's Research
Parkinson Disease
United States
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor FluctuationsRecruiting
NCT07514858Phase 2Updated Sep 8, 2026
Sponsor: H. Lundbeck A/S
Parkinson's Disease
United States
Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson DiseaseActive Not Recruiting
NCT07808346NAUpdated Sep 8, 2026
Sponsor: University of Colorado, Denver
Parkinson's Disease (PD)
United States
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)Recruiting
NCT06345729Phase 3Updated Sep 8, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Brazil +22 more
Positron Emission Tomography (PET) Imaging in People With Gaucher MutationsCompleted
NCT00302146N/AUpdated Sep 8, 2026
Sponsor: National Human Genome Research Institute (NHGRI)
Parkinson Disease · Gaucher Disease
United States
Monoamine Oxidase B PET/CT in Various MAO-B-Related DiseaseRecruiting
NCT07685873N/AUpdated Sep 8, 2026
Sponsor: Tianjin Medical University
Parkinson Disease · Parkinson Disease Dementia · Parkinson's Disease and Parkinsonism
China
Real-world Patient Experiences With Inbrija®Not Yet Recruiting
NCT07797790N/AUpdated Sep 4, 2026
Sponsor: Merz Therapeutics GmbH
Parkinson Disease (PD) · Parkinson's Disease · Off Episodes of Parkinson Disease
Austria
A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's MedicationsRecruiting
NCT07330258N/AUpdated Sep 4, 2026
Sponsor: Bayer
Parkinson's Disease
United States
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic TherapyNot Yet Recruiting
NCT07804615Phase 2Updated Sep 4, 2026
Sponsor: Vima Therapeutics
PARKINSON DISEASE (Disorder)
United States, Canada
Impact of Subthalamic Nucleus Deep Brain Stimulation on COGnitive and PSYchiatric Symptoms in Parkinson's DiseaseRecruiting
NCT07777419NAUpdated Sep 4, 2026
Sponsor: Insel Gruppe AG, University Hospital Bern
Parkinsons Disease (PD)
Switzerland
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's DiseaseActive Not Recruiting
NCT04777331Phase 2Updated Sep 4, 2026
Sponsor: Hoffmann-La Roche
Parkinsons Disease
United States, Austria, Canada, France, Italy +4 more
Evaluation of the Effects of Levodopa-Benserazide Drug Combination on Periodontal Status in Patients With Parkinson's DiseaseActive Not Recruiting
NCT07405268N/AUpdated Sep 4, 2026
Sponsor: Saglik Bilimleri Universitesi
Parkinson Disease (PD) · Periodontitis · Periodontal Diseases
Turkey (Türkiye)
Testing the Feasibility of an Online Guided-writing Intervention Designed for Informal Caregivers of People With Parkinson's DiseaseCompleted
NCT07804953NAUpdated Sep 4, 2026
Sponsor: University of Reading
Psychological
United Kingdom
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)Recruiting
NCT06170788Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Brazil, Canada +21 more
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and ApathyRecruiting
NCT07461220Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Integrative Research Laboratories AB
PARKINSON DISEASE (Disorder) · Apathy · Safety
Bulgaria, Germany, Poland, Spain
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRecruiting
NCT07174310Phase 3Updated Sep 3, 2026
Sponsor: Hoffmann-La Roche
Parkinson's Disease
United States, Australia, Austria, Brazil, Canada +12 more
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)Recruiting
NCT06312176Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +35 more
Natural History Protocol for Movement DisordersRecruiting
NCT05413291N/AUpdated Sep 3, 2026
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Movement Disorder · Tremor · Parkinson's Disease
United States
DOES HIPPOTHERAPY HAVE AN EFFECT ON MOBILITY, GAIT, BALANCE AND PERCEIVED HEALTH-RELATED QUALITY OF LIFE IN PERSONS WITH PARKINSON'S DISEASE?Recruiting
NCT07802509NAUpdated Sep 3, 2026
Sponsor: Klinik Valens
Parkinson Disease
Switzerland
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related PsychosisRecruiting
NCT05824728Phase 2Updated Sep 3, 2026
Sponsor: Johns Hopkins University
Parkinson Disease Psychosis
United States
Predicting Cognition After DBS for Parkinson's Disease 2Active Not Recruiting
NCT06272968N/AUpdated Sep 3, 2026
Sponsor: Charite University, Berlin, Germany
Cognitive Impairment
Germany
Cortical Electrophysiology of Response Inhibition in Parkinson's DiseaseRecruiting
NCT06234995Phase 4Updated Sep 3, 2026
Sponsor: Emory University
Parkinson Disease
United States

Previous page Next page